How Big Is the IVD Market? What the 2025 Estimates Actually Say

Published

The 2025 estimates side by side

Three published figures cover the same market year with different scopes. Grand View Research’s in vitro diagnostics industry report (accessed November 2026) values the 2025 market at USD 107.4 billion, rising to USD 112.5 billion in 2026 and USD 163.0 billion by 2033 at a 5.4% CAGR (2026–2033). Kalorama Information’s 19th edition of The Worldwide Market for In Vitro Diagnostic Tests (published September 4, 2025) reports US$115.6 billion for 2025 with US$150.4 billion projected by 2030. MarketsandMarkets’ published abstract cites roughly USD 104 billion for 2025. The estimates agree on direction and rough scale; they disagree on where the boundary of "the market" sits.

Why the numbers differ: scope, not error

Market-size disagreements are almost always definition disagreements. One estimate counts only regulated IVD consumables; another adds research-use-only reagents, which are a large business adjacent to clinical diagnostics. Self-test and over-the-counter products sit inside some definitions and outside others. Instruments and service contracts may be counted once, amortized, or excluded. An earlier Kalorama edition working with a broader definition reported USD 124 billion, while Kalorama’s own 2023 market overview reported USD 106 billion — same publisher, same market, different scope. When a page quotes a single number without scope and date, it is hiding the only two facts that make the number interpretable.

What converges: the 2030 projection

Despite the different 2025 baselines, the major projections land in the same place: roughly US$150 billion by 2030, at 5.4–5.6% annual growth. Kalorama reaches US$150.4 billion by 2030; Grand View Research passes through a comparable trajectory to USD 163.0 billion by 2033. For planning purposes, the defensible statement is "mid-single-digit annual growth to about US$150 billion by 2030" — not any single starting point.

What this means for IVD buyers

For a laboratory or distributor, segment size is context for supplier behavior, not a selection criterion. A large and growing segment means active vendor competition and more new-product announcements; it does not change whether a specific assay is registered in your market, whether the manufacturer services your country, or what the reagent contract costs per test. Those are answerable only per supplier and per product — which is the layer IVDmap’s product and company records work at, with each published specification traced to its source page.

How this page is kept honest

Every figure above carries its publisher, edition or report name, and publication or access date. Where a number could not be independently re-verified by IVDmap, it is attributed to the publisher’s own published abstract and linked. This page is dated November 2026; estimates are revised annually by their publishers, and figures should always be read together with their scope statement, never alone.

Key takeaways

Published estimates place the 2025 global in vitro diagnostics market between roughly US$105 billion and US$116 billion: Grand View Research reports USD 107.4 billion for 2025, and Kalorama Information’s 19th-edition worldwide IVD report reports US$115.6 billion. Both project the market to reach about US$150 billion by 2030 at roughly 5.4% annual growth. The spread is a scope difference, not an error — each figure covers a different definition of the market.

  • Grand View Research: USD 107.4 billion in 2025, USD 112.5 billion in 2026, USD 163.0 billion by 2033 (CAGR 5.4%, 2026–2033).
  • Kalorama Information (19th edition, published September 2025): US$115.6 billion in 2025, projected US$150.4 billion by 2030.
  • Both major projections converge on roughly US$150 billion by 2030 despite the different 2025 baselines.
  • Earlier Kalorama editions illustrate the scope effect: the 2023 overview reported USD 106 billion, while a broader-definition edition reported USD 124 billion.
  • These are analyst estimates, not measurements — use them for segment context, not as a substitute for verifying individual suppliers and products.

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-11-18

Updated

2026-11-18

Disclaimer

professional use

FAQ

Common questions

What is the global IVD market size in 2025?

Depending on the analyst and the scope of the definition, roughly US$105–116 billion. Grand View Research values it at USD 107.4 billion for 2025; Kalorama Information’s 19th-edition report puts it at US$115.6 billion. Both figures were published in 2025 and are estimates of the market, not audited measurements.

Why do IVD market size estimates differ so much?

Scope. Definitions differ on whether they include research-use-only reagents, over-the-counter self-tests, instrument sales versus consumables, and associated services. Currency re-basing and retrospective revisions add further spread. An earlier Kalorama edition using a broader definition reported USD 124 billion for the same market that a 2023 overview put at USD 106 billion.

What growth rate is projected for IVD?

Around 5.4% annually. Grand View Research projects a 5.4% CAGR for 2026–2033 (to USD 163.0 billion by 2033), and Kalorama’s 2025–2030 projection implies about 5.4% per year (to US$150.4 billion by 2030).

Does market size matter when choosing an IVD supplier?

Only as context. Market size says a segment is active; it says nothing about whether a specific supplier’s product is registered in your market, supported locally, or fit for your workflow. A structured verification checklist — regulatory status on the exact product, quality system, evidence-backed claims, service continuity, cost per test — is the decision tool. See IVDmap’s supplier verification guide (https://ivdmap.com/insights/how-to-choose-an-ivd-supplier).

Explore more